ArticleBrain and behavior2025
Associations Between Malignant Tumors and Alzheimer's Disease: A Cross-Sectional Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations Between Malignant Tumors and Alzheimer's Disease: A Cross-Sectional Study.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAlthough there is potential overlap in the pathological and physiological mechanisms underlying malignant tumors and Alzheimer's disease (AD), a significant gap remains in the epidemiological evidence supporting their association. We used data from the National Health and Nutrition Examination Survey (NHANES) to elucidate the epidemiological relationship between malignant tumors and AD.
methodsWe analyzed data from NHANES from 2013 to March 2020, prior to the COVID-19 pandemic, including 9274 participants aged ≥ 20 years. Multivariate logistic regression was used to explore the link among malignant tumors, tumor types, and AD risk. Sensitivity analyses were performed to evaluate the robustness of the association with neurofilament light chain levels, composite cognitive function scores, and different analytic populations. Additionally, subgroup analyses were performed to explore the association between malignancy and AD risk in specific subpopulations.
resultsAmong the 9274 participants included in the study, 1432 were identified as having malignant tumors. There was a significant association between malignant tumors and AD [adjusted odds ratio (aOR): 1.55; 95% confidence interval (CI): 1.27-1.89; p < 0.001]. The risk of AD was higher in patients with colorectal and prostate cancer compared to those with other malignancies. Sensitivity analysis of neurofilament light chain levels suggested that malignant tumors may contribute to the development of mild cognitive impairment (aOR: 1.52; 95% CI: 1.01-2.27; p = 0.044). Subgroup analysis revealed that AD risk following a malignant tumor diagnosis was higher in people < 65 years old and those with medium-high incomes.
conclusionsMalignant tumors may be significantly associated with increased AD risk, particularly in patients with colorectal and prostate cancer. Moreover, individuals < 65 years old and those with middle-high income had increased risk of developing AD following a malignancy. These findings underscore the significance of early AD detection and prevention in patients with a history of malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.